The reduction in CRP in the substitution trial of a sweetened soy beverage, which included participants with non-alcoholic fatty liver disease, is supported by systematic reviews and meta-analyses demonstrating improvements in inflammatory biomarkers from the consumption of soy [131,132], including one specifically showing benefit of soy protein [133]. Here, CRP is linked to alcoholic fatty liver disease.